

Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma

Information for the public

Published: 11 January 2023

www.nice.org.uk

Nivolumab with platinum- and fluoropyrimidine-based chemotherapy is available on the NHS. It is a possible treatment for gastric (stomach), gastro-oesophageal junction or oesophageal cancer in adults if:

- they have not had treatment before
- their cancer is advanced or has spread to other parts of the body (metastatic)
- their tumours:
 - are HER2-negative
 - express a protein called PD-L1 with a combined positive score of 5 or more.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpages on stomach cancer](#) and [oesophageal cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Guts UK](#), 0207 486 0341
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4921-2